Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).

J Immunother Cancer · 2026 · PMC12983688 · PMID 41819545

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significancep=0.12not close (p > 0.1)

Similarly, patients in the group “One+lesion ↑ > 5 mm & One+lesion ↓ > 5 mm” exhibited poorer overall survival (HR 2.37; 95% CI 1.26 to 4.48; p=0.008), although the association with PFS did not reach statistical significance (HR 1.67; 95% CI 0.88 to 3.15; p=0.12).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.